U.S. drugmaker Pfizer has clinched a $10 billion deal for obesity drug developer Metsera , capping a fierce biotech bidding ...

The US drug giant beat Novo Nordisk in the $10 bln battle for biotech Metsera with the help of the Federal Trade Commission.

(Reuters) -Shares of Metsera fell over 15% in premarket trading on Monday, after the weight-loss drug developer accepted a ...

The announcement of the deal signaled an end to the bidding war for Metsera between Pfizer and Novo Nordisk, the Danish maker ...

Pfizer has signed a deal to purchase Metsera Inc., an obesity drugmaker in the development stage, after winning a bidding war ...

Pfizer is preparing to sweeten its offer again for Metsera, the weight-loss drug startup at the center of a bidding war that ...

Pfizer is working to deal with typical business issues in the drug space, but its attempt at a solution has become very ...

The tussle between the two drugmakers has spread from the boardroom to the courtroom to the corridors of Washington ...

Oliver Barnes Pfizer and Novo Nordisk duked it out for who will own Metsera — a coveted biotech that’s developing ...

Pfizer Inc. acquires Metsera, Inc., beating Novo Nordisk, for up to $86.25/share. Click for my analysis of the deal and what ...

“No need for a reunion show: This seasons Real Housewives of Biopharma comes to a close with Pfizer’s winning bid for Metsera ...

There’s room for more than one winner in this race for GLP-1 weight loss supremacy, but some of these winners are going to be ...